 CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 12, 2021 GLOBE NEWSWIRE -- iTeos Therapeutics, Inc. Nasdaq: ITOS, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights. 